Dr. Federman on Use of Nanotechnology in Sarcomas

Noah Federman, MD
Published: Monday, Jul 18, 2016


Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Nanotechnology is being examined at UCLA in pediatric patients with bone and soft tissue sarcomas, Federman explains. Nanotechnology is comprised of very small molecules to carry cytoxic agents. Additionally, the molecules can be coated to target cancer cells.

This could offer the ability to spare select organs in the body while delivering higher doses of therapy directly to cancer cells. Thus far, this has been in only tested in preclinical models, Federman adds.

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Nanotechnology is being examined at UCLA in pediatric patients with bone and soft tissue sarcomas, Federman explains. Nanotechnology is comprised of very small molecules to carry cytoxic agents. Additionally, the molecules can be coated to target cancer cells.

This could offer the ability to spare select organs in the body while delivering higher doses of therapy directly to cancer cells. Thus far, this has been in only tested in preclinical models, Federman adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x